Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Treasury Shares (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Treasury Shares for 3 consecutive years, with -$539000.0 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Treasury Shares changed N/A year-over-year to -$539000.0, compared with a TTM value of -$539000.0 through Sep 2024, changed N/A, and an annual FY2023 reading of $1.8 million, up 17.47% over the prior year.
  • Treasury Shares was -$539000.0 for Q3 2024 at Oramed Pharmaceuticals, down from $118522.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $4.5 million in Q2 2022 and bottomed at -$539000.0 in Q3 2024.
  • Average Treasury Shares over 3 years is $1.5 million, with a median of $1.6 million recorded in 2022.
  • Peak annual rise in Treasury Shares hit 17.47% in 2023, while the deepest fall reached 17.47% in 2023.
  • Year by year, Treasury Shares stood at $1.6 million in 2022, then rose by 17.47% to $1.8 million in 2023, then crashed by 129.38% to -$539000.0 in 2024.
  • Business Quant data shows Treasury Shares for ORMP at -$539000.0 in Q3 2024, $118522.0 in Q2 2024, and $1.8 million in Q4 2023.